Threshold Presents Clinical Trial Data From a Phase 1/2 Clinical Trial of TH-302 at ASCO Gastrointestinal Conference
25. Januar 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 25, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Provides Clinical Development Update at J.P. Morgan Healthcare Conference
12. Januar 2010 08:45 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold to Present at J.P. Morgan Healthcare Conference
05. Januar 2010 08:55 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the...
Threshold Pharmaceuticals Announces Preclinical Multiple Myeloma Data
07. Dezember 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced preclinical results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302
18. November 2009 08:45 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold to Present at Lazard Capital Markets Healthcare Conference
16. November 2009 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the...
Threshold Pharmaceuticals Announces Clinical Development Results for Cancer Candidate TH-302
12. November 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug,...
Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting
06. November 2009 08:45 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Reports Third Quarter 2009 Financial Results
05. November 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009.
The net loss for...
Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals
15. Oktober 2009 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif. and PRINCETON, N.J., Oct. 15, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), and Eleison Pharmaceuticals, Inc., today announced the execution of a...